Ultragenyx Pharmaceutical Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Novato, CA
RARE chart
What traders are saying about $RARE
Latest postsUltragenyx Pharmaceutical Inc. news
- Mereo BioPharma Reports Third Quarter 2026 Financial Results
Yahoo Finance ·
- Ultragenyx Pharmaceutical Inc. (UP0.DE) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada ·
- Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Privium Fund Management B.V.
MarketBeat ·
- Ultragenyx Pharmaceutical Stock Price Forecast. Should You Buy RARE?
StockInvest.us ·
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharmadive.com ·
- Ultragenyx Pharmaceutical Inc (UP0.SG) Seasonal returns chart
Yahoo Finance Australia ·
- Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Yahoo Finance ·
- Children with Sanfilippo syndrome have limited treatment options. A therapy is under UK review.
Stock Titan ·
- Where Does Ultragenyx Pharmaceutical (RARE) Value Sit After Cost Cuts?
Simply Wall St ·
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $22.00 Price Target at Citigroup
MarketBeat ·
- Citigroup maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $22 from $32
TradingView ·
- Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
MarketBeat ·
Ultragenyx Pharmaceutical Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M |
| Diluted EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 |
| Total assets (year end) | $1.53B | $1.50B | $1.49B | $1.55B |
| Cash and equivalents (year end) | $421.0M | $174.0M | $214.0M | $132.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Ultragenyx Pharmaceutical Inc.
- Ticker
- RARE (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Novato, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1515673
Frequently asked questions
What exchange is Ultragenyx Pharmaceutical Inc. listed on?
Ultragenyx Pharmaceutical Inc. trades on the Nasdaq under the ticker symbol RARE.
What industry is Ultragenyx Pharmaceutical Inc. in?
Ultragenyx Pharmaceutical Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Ultragenyx Pharmaceutical Inc. headquartered?
Ultragenyx Pharmaceutical Inc.'s business address on file with the SEC is in Novato, CA.
When does Ultragenyx Pharmaceutical Inc.'s fiscal year end?
Ultragenyx Pharmaceutical Inc.'s fiscal year ends on December 31.
How much revenue did Ultragenyx Pharmaceutical Inc. report?
Ultragenyx Pharmaceutical Inc. reported $673.0M in revenue for calendar year 2025, according to its SEC filings.